<DOC>
	<DOCNO>NCT00046917</DOCNO>
	<brief_summary>Phase I trial study effectiveness combine alvocidib , irinotecan hydrochloride , cisplatin treat patient advance solid tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose flavopiridol ( alvocidib ) , irinotecan ( irinotecan hydrochloride ) , cisplatin patient advance solid tumor . II . Determine clinical pharmacokinetics regimen patient . III . Determine , preliminarily , therapeutic activity regimen patient . OUTLINE : This dose-escalation study . Patients stratify accord number prior treatment regimen ( 0 1 v 1 ) . Patients receive irinotecan hydrochloride intravenously ( IV ) 30 minute follow immediately cisplatin IV 30 minute follow 7 hour later alvocidib IV 1-4.5 hour weekly 2 week . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos cisplatin , alvocidib , irinotecan hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 12 additional patient treat recommended phase II dose .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm locally advanced metastatic solid tumor refractory standard therapy standard therapy exist Evaluable disease No previously untreated CNS metastasis No primary CNS tumor Performance status Karnofsky 60100 % Performance status ECOG 02 Not specify WBC least 3,000/mm^3 Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 2.0 mg/dL AST ALT great 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min No cardiac arrhythmia No congestive heart failure No myocardial infarction within past 6 month HIV negative No neuropathy grade 2 great No serious uncontrolled infection No medical condition reason would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 2 month study participation At least 4 week since prior immunotherapy At least 1 week since prior irinotecan cisplatin alone At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Not specify At least 4 week since prior radiotherapy Not specify Recovered prior therapy No concurrent vitamin , antioxidant , herbal supplement except daily multivitamin No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>